Equities analysts predict that Novan Inc (NASDAQ:NOVN) will post earnings per share of ($0.23) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Novan’s earnings, with the lowest EPS estimate coming in at ($0.30) and the highest estimate coming in at ($0.15). Novan reported earnings per share of ($0.21) in the same quarter last year, which indicates a negative year-over-year growth rate of 9.5%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, May 21st.

According to Zacks, analysts expect that Novan will report full-year earnings of ($1.05) per share for the current financial year, with EPS estimates ranging from ($1.23) to ($0.87). For the next fiscal year, analysts forecast that the business will post earnings of ($0.84) per share, with EPS estimates ranging from ($0.95) to ($0.72). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Novan.

A number of equities research analysts have commented on NOVN shares. Zacks Investment Research cut shares of Novan from a “buy” rating to a “hold” rating in a research note on Tuesday, February 12th. JMP Securities cut shares of Novan from an “outperform” rating to a “market perform” rating in a research note on Friday, March 29th. Finally, ValuEngine cut shares of Novan from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $6.75.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NOVN. Renaissance Technologies LLC raised its position in shares of Novan by 52.0% during the 3rd quarter. Renaissance Technologies LLC now owns 89,700 shares of the company’s stock worth $250,000 after acquiring an additional 30,700 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Novan during the 4th quarter worth about $25,000. RMB Capital Management LLC raised its position in shares of Novan by 45.5% during the 4th quarter. RMB Capital Management LLC now owns 32,000 shares of the company’s stock worth $27,000 after acquiring an additional 10,000 shares in the last quarter. Deutsche Bank AG raised its position in shares of Novan by 4,462.7% during the 4th quarter. Deutsche Bank AG now owns 47,863 shares of the company’s stock worth $39,000 after acquiring an additional 46,814 shares in the last quarter. Finally, Prospera Financial Services Inc raised its position in shares of Novan by 44.3% during the 1st quarter. Prospera Financial Services Inc now owns 87,552 shares of the company’s stock worth $79,000 after acquiring an additional 26,860 shares in the last quarter. Institutional investors own 6.55% of the company’s stock.

NASDAQ NOVN traded up $0.03 on Friday, reaching $1.41. 200 shares of the stock were exchanged, compared to its average volume of 1,109,337. Novan has a one year low of $0.65 and a one year high of $3.32.

About Novan

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Story: Investing in Growth Stocks

Get a free copy of the Zacks research report on Novan (NOVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novan (NASDAQ:NOVN)

Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.